- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05718791
CXCL9 and EASIX for Prediction of Acute Graft Versus Host Disease
April 22, 2024 updated by: Shatha Farhan, Henry Ford Health System
CXC-chemokine Ligand 9 (CXCL9) and Endothelial Activation and Stress Index (EASIX) for Prediction of Acute Graft Versus Host Disease
The prediction of severe acute GVHD before it occurs is of high importance for ensuing clinical decisions and overall success of allogeneic SCT.
The key immunologic signatures associated with clinical outcomes after different graft versus host disease prophylaxis methods or peripheral blood stem cell transplant are largely unknown.
Study Overview
Study Type
Observational
Enrollment (Estimated)
100
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: shatha farhan, MD
- Phone Number: 3137133910
- Email: sfarhan1@hfhs.org
Study Locations
-
-
Michigan
-
Detroit, Michigan, United States, 48202
- Recruiting
- Henry Ford Health System
-
Contact:
- shatha farhan
- Phone Number: 313-916-5002
- Email: sfarhan1@hfhs.org
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 80 years (Adult, Older Adult)
Accepts Healthy Volunteers
N/A
Sampling Method
Non-Probability Sample
Study Population
Patients >18 year old admitted for allo SCT PB for malignant disease
Description
Inclusion Criteria:
- Patients >18 year old admitted for allo SCT PB for malignant disease.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
predictors of acute GVHD
Time Frame: CXCL9 combined with EASIX calculated at day 28 +/- 2 post SCT can be used as predictors of acute GVHD by day 100.
|
CXCL9 combined with EASIX can be used as predictors of acute GVHD
|
CXCL9 combined with EASIX calculated at day 28 +/- 2 post SCT can be used as predictors of acute GVHD by day 100.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 10, 2023
Primary Completion (Estimated)
March 30, 2026
Study Completion (Estimated)
March 30, 2026
Study Registration Dates
First Submitted
January 30, 2023
First Submitted That Met QC Criteria
January 30, 2023
First Posted (Actual)
February 8, 2023
Study Record Updates
Last Update Posted (Actual)
April 23, 2024
Last Update Submitted That Met QC Criteria
April 22, 2024
Last Verified
April 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- hhf
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on GVHD,Acute
-
Shanghai Jiao Tong University School of MedicineCompleted
-
Mats RembergerThe Swedish Research CouncilRecruitingGVHD, AcuteSweden, Norway, Denmark
-
CSL BehringTerminated
-
Weill Medical College of Cornell UniversityTerminatedGlucocorticosteroid Refractory Acute GVHDUnited States
-
Duke UniversityRecruiting
-
Shanghai iCELL Biotechnology Co., Ltd, Shanghai...Not yet recruiting
-
UNC Lineberger Comprehensive Cancer CenterUniversity of North Carolina, Chapel HillCompleted
-
EquilliumBiocon LimitedRecruitingGraft Versus Host Disease | GVHD | aGVHD | Acute-graft-versus-host Disease | Acute GVHDUnited States, Korea, Republic of, Israel, Spain, Germany, Belgium, Italy, Australia, France, Canada, Portugal
-
Chinese PLA General HospitalRecruiting
-
EquilliumBiocon LimitedRecruitingGVHD | GVHD, Acute | aGVHD | Acute-graft-versus-host DiseaseUnited States
Clinical Trials on blood sample
-
Medical University of WarsawCompletedArthroplasty | Platelet Aggregation | Methylmethacrylate EmbolismPoland
-
Memorial Sloan Kettering Cancer CenterActive, not recruiting
-
Meir Medical CenterCompleted
-
First Affiliated Hospital of Zhejiang UniversityRecruitingComplication | Hematologic Malignancy | Hematopoietic Stem Cell Transplantation | Chronic Graft-versus-host-diseaseChina
-
University Hospital, BordeauxMinistry for Health and Solidarity, FranceRecruitingImmune Thrombocytopenia | Autoimmune Hemolytic Anemia | Autoimmune NeutropeniaFrance
-
University Hospital, ToursCompletedMetastatic Prostate Cancer | Circulating Tumor DNAFrance
-
University Hospital, BordeauxActive, not recruitingSystemic Lupus Erythematosus | Systemic SclerodermaFrance
-
University Hospital, BordeauxCompletedRenal Function Disorder | Chronic Renal Diseases
-
University Hospital, ToursNot yet recruitingRenal Transplant | ConversionFrance